Literature DB >> 7866541

Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma.

L P Rivory1, J Robert.   

Abstract

Irinotecan, also known as CPT-11 (I), is a potent semi-synthetic derivative of 20(S)-camptothecin (CPT). Like all known active derivatives of CPT, the lactone forms of I and its active metabolite SN-38 (II) are reversibly hydrolysed to inactive carboxylate forms. We describe a sensitive and selective HPLC method using the ion-pairing reagent tetrabutylammonium phosphate (TBAP) which allows the simultaneous determination of the carboxylate and lactone forms of I and II in human plasma samples following the precipitation of plasma proteins with an ice-cold mixture of acetonitrile and methanol. The mobile phase was 0.075 M ammonium acetate buffer (pH 6.4)-acetonitrile (78:22, v/v) containing 5 mM TBAP. Separation of the compounds was performed on a radially-compressed C18 column. The limits of quantitation in human plasma were 2 and 10 ng/ml for the two forms of II and I, respectively. In addition, we propose the use of CPT lactone both as an internal standard and as a "watchdog" for sample status. Under unsuitable storage conditions, CPT elutes increasingly in its carboxylate form thereby alerting the operator of possibly erroneous determinations of the concentrations of both forms of I and II. The retention times of the peaks of interest are well separated from the solvent front. This enables the detection of early eluting metabolites. The method was successfully used for monitoring of the two forms of I and II in patients treated with I.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7866541     DOI: 10.1016/0378-4347(94)00340-8

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Appl        ISSN: 1572-6495


  11 in total

1.  Quantification of irinotecan, SN38, and SN38G in human and porcine plasma by ultra high-performance liquid chromatography-tandem mass spectrometry and its application to hepatic chemoembolization.

Authors:  Xiaohong Chen; Cody J Peer; Raul Alfaro; Tian Tian; Shawn D Spencer; William D Figg
Journal:  J Pharm Biomed Anal       Date:  2012-01-16       Impact factor: 3.935

Review 2.  Clinical pharmacokinetics of irinotecan.

Authors:  G G Chabot
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

3.  Excretion into gastrointestinal tract of irinotecan lactone and carboxylate forms and their pharmacodynamics in rodents.

Authors:  K Arimori; N Kuroki; A Kumamoto; N Tanoue; M Nakano; E Kumazawa; A Tohgo; M Kikuchi
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

4.  Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan.

Authors:  L P Rivory; J Robert
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

5.  A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.

Authors:  Archie N Tse; David S Klimstra; Mithat Gonen; Manish Shah; Tahir Sheikh; Rachel Sikorski; Richard Carvajal; Janet Mui; Caroll Tipian; Eileen O'Reilly; Ki Chung; Robert Maki; Robert Lefkowitz; Karen Brown; Katia Manova-Todorova; Nian Wu; Merrill J Egorin; David Kelsen; Gary K Schwartz
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

6.  Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.

Authors:  Kazuhiko Arimori; Noriaki Kuroki; Muneaki Hidaka; Tomomi Iwakiri; Keishi Yamsaki; Manabu Okumura; Hiroshige Ono; Norito Takamura; Masahiko Kikuchi; Masahiro Nakano
Journal:  Pharm Res       Date:  2003-06       Impact factor: 4.200

7.  A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies.

Authors:  Paula M Fracasso; Kerry J Williams; Ronald C Chen; Joel Picus; Cynthia X Ma; Matthew J Ellis; Benjamin R Tan; Timothy J Pluard; Douglas R Adkins; Michael J Naughton; Janet S Rader; Matthew A Arquette; James W Fleshman; Allison N Creekmore; Sherry A Goodner; Lisa P Wright; Zhanfang Guo; Christine E Ryan; Yu Tao; Eliane M Soares; Shi-Rong Cai; Li Lin; Janet Dancey; Michelle A Rudek; Howard L McLeod; Helen Piwnica-Worms
Journal:  Cancer Chemother Pharmacol       Date:  2010-08-08       Impact factor: 3.333

8.  A combined experimental and mathematical approach for molecular-based optimization of irinotecan circadian delivery.

Authors:  Annabelle Ballesta; Sandrine Dulong; Chadi Abbara; Boris Cohen; Alper Okyar; Jean Clairambault; Francis Levi
Journal:  PLoS Comput Biol       Date:  2011-09-08       Impact factor: 4.475

9.  CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues.

Authors:  S Guichard; C Terret; I Hennebelle; I Lochon; P Chevreau; E Frétigny; J Selves; E Chatelut; R Bugat; P Canal
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

10.  Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients.

Authors:  E Rouits; V Charasson; A Pétain; M Boisdron-Celle; J-P Delord; M Fonck; A Laurand; A-L Poirier; A Morel; E Chatelut; J Robert; E Gamelin
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.